Legal Representation
Attorney
James M. Slattery
USPTO Deadlines
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 17, 2015 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Aug 17, 2015 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jan 13, 2015 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 18, 2014 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 18, 2014 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 29, 2014 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 12, 2014 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Oct 11, 2014 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Sep 26, 2014 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 26, 2014 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 25, 2014 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 25, 2014 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 3, 2014 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 3, 2014 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 3, 2014 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 2, 2014 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 14, 2014 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 3, 2014 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemical compounds for use as an adjuvant in the manufacture of pharmaceutical preparations
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
Pharmaceutical preparations and compounds for the prevention and treatment of Crohn's disease, multiple sclerosis, viral infections, lipodystrophy syndrome, HIV/AIDS, cancer, cell growth related disorders, cell proliferation related disorders, inflammatory diseases, ulcerative diseases, autoimmune diseases, autism, Parkinson's disease and lymphoproliferative syndrome; pharmaceutical preparations and compounds for reducing side effects in cancer treatment; pharmaceutical preparations and compounds for stimulating the immune system in an immunocompromised patient
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
001
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"BIOSCIENCES"